

Datasheet for ABIN7200671

Recombinant anti-CTLA-4 (Ipilimumab Biosimilar) antibody



[Go to Product page](#)

Overview

| | |
|----------------|---|
| Quantity: | 1 mg |
| Target: | CTLA-4 (Ipilimumab Biosimilar) |
| Reactivity: | Human |
| Host: | Mouse |
| Antibody Type: | Recombinant Antibody |
| Clonality: | Monoclonal |
| Conjugate: | This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated |
| Application: | Flow Cytometry (FACS), In vivo Studies (in vivo) |

Product Details

| | |
|------------------|---|
| Purpose: | Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody |
| Immunogen: | The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line. |
| Isotype: | IgG1 kappa |
| Specificity: | The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4. |
| Characteristics: | Recombinant fully human IgG1 monoclonal antibody. |
| Purification: | Protein A affinity column |
| Purity: | > 95% by SDS-PAGE under reducing conditions and HPLC. |
| Sterility: | 0.2 µm filtered |
| Endotoxin Level: | < 1 EU per 1 mg of the protein by the LAL method. |

Target Details

| | |
|--------------|---|
| Target: | CTLA-4 (Ipilimumab Biosimilar) |
| Abstract: | CTLA-4 (Ipilimumab Biosimilar) Products |
| Target Type: | Biosimilar |
| Background: | <p>What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.</p> <p>Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.</p> <p>Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.</p> |

Application Details

| | |
|--------------------|---|
| Application Notes: | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab. |
| Restrictions: | For Research Use only |

Handling

| | |
|------------------|---|
| Format: | Liquid |
| Concentration: | 1 mg/mL |
| Buffer: | PBS, pH 7.4, no stabilizers or preservatives. |
| Preservative: | Without preservative |
| Handling Advice: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Storage: | -20 °C |
| Storage Comment: | 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Expiry Date: | 12 months |